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Patients frequently present to the emergency department 
(ED) with symptoms of influenza, the common cold, or a 
confusine combination of both svmotoms. As most California  -  . . 
emergency physicians know,  these symptoms appear more 
frequently in the winter months when large sections of ED waiting 
rooks may  be  filled with flu or UIU patients  It  is sometimes 
difficult to distineuish between influenza and  the "common  cold." 
Influenza A and 6 are caused by an onhomyxovirus, whereas 
symptoms of the common cold can be caused by one of many 
viruses including rhinovirus, coronaviruses. RSV or adenovh.' 
Influenw A is a zoonotic infection thu also infecis oies. birds.  .  .. 
horses, and seals.  Indeed, the severe 1918 pandemic that resulted 
in millions of deaths worldwide is believed to bave originated 
from pigs.' 
Pinmosis:  The following table has been utilized in some 
EDs to help discriminate between influenza and the common cold: 
I  I 
Onset  1 Abmot  1 Gradual 
I 100-104~~  I IOD'F or ~ess 
Common  1 Occasional 
Headache  I  Common  1  Variable  ..--- 
Rhinitis  I  Occasional  I  common 
The specificity and sensitivity of the above table have never 
been scientifically tested.  Accurately diagnosing influenza A orB 
may be more difficult than the table above suggests. In addition 
to overlapping symptoms caused by  "URI and Cold" viruses, 
other viruses cause influenza-like symptoms including enterovi- 
ruses, paramyxoviruses, and even "tropical"  fevers such as 
Dengue.  For example. 98% of persons who acquired West-Nile 
fever in New York in 1999 were initially diagnosed as having the 
flu. 
The gold standard fbr diagnosing influenza A and B is a viml 
culture of nasal-pharyngeal and/or ihroac samples using dacron 
.  swabs which need to be sent in appropriate viral transport media 
(eg. M4 Tmport  Media) to the lab where it is cultured in several 
lines of cells.  Diagnosis of influenza  is made in the lab once 
specific cytopathic effect is observed or hemadsorption testing is 
positive.  Confimtion is then performed using the infected 
cultured cell lines by staining them with fluorescent antibody. 
The process may tske from three to seven days:  long after the 
patient has left the ED and well past the time when drug therapy 
could be efficacious. Dict.immunofluorexent tests on fresh 
specimens are also available in some labs, but are labor intensive 
and have sensitivity lower than culture methods.  These tests 
require specially trained lab personnel far interpretation, not 
generally available all shifts, even in large medical centers. 
In order to overcome ~&s  obstacle, several "bedside"  tesu 
have become available. In reality, many of these are not bedside 
tests as they generally require 30.60 minutes of  time to perform 
multiple steps to complete the test,?  "Rapid  tests" are best done by 
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a lab adjacent to the ED. Several disadvantages to performing these rapid 
diagnostic tests include the cost of the laboratory personnel to perform the 
lest, the actual cost of the test itself, and the fact that the test may miss 
many patients who actually have influenza A or B.  Test sensitivities are 
generally in the 60.70%  range.  Recently, the FDA waived Federal CLIA 
requirements and approved an actual ten minute "QuickVue" bedside test 
with 7080% sensitivity. Because of cost, availabity. and sensitivity 
issues most EM physicians diagnose influenza on clinical criteria alone. 
Treatment.  Prevention is the mosteffeciwe  treatment as with other 
diseases.  The CDC has published recommendations for high risk groups 
who should be vnccinaled, which includes all health care personnel.' 
Amantadme and rimantadine have been approved for use against influenza 
A for many years.  These have generally not been popularly used in EDs. 
Disadvantages of these drugs includes lack of efficacy against influenza B, 
potential side effects, and rapid development of viral resistance. 
Two new drugs have been marketed for treatment of influenza A and B 
recently.  These are the neurminidase inhibitors, oseltnmivir and 
zanamivir.  Oseltamivir is taken orally. 75 mg twice and zanamivir via an 
inhalation appnratus, lOmg twice a day?  Multiple studies bave demon- 
smed  their efficacy. These agents work by inhibiting influenzavirus 
neuraminidase, aglyco-protein spike on the outside of the virus envelope 
needed for successful cellular release and transmission within the body. 
These new agents need to be administered within 36 houn of  onset of 
symptoms to be effective. Recent studies also show efficacy in the 
prophylactic use in preventing influenza A and  B, an exciting expansion in 
use of these agents.  The prophylactic dose is one-half the acute dose. 
There are several advantages to neuraminidase inhibitors compared with 
amantadine including less evolution of resistance, efficacy against 
influenza B.  dramatic reduction in symptom, even in patients who do have 
a full course of flu, and fewer side effects. 
In a study of 445 patients by the Mist group 1, zanamivir was given to 
one-half and placebo to the others wirhin 36 hours of symptom onse~~  The 
dmtion of the flu was reduced by  1.5  days in normal groups and 2.5 days 
in high risk groups. A significant  decrease in the severity of illness in 
patients @eated  with zanamivir allowed them to resume normal activities 
much swner. 
A recent study by Treanor compared areltamivir to placebo?  lhis 
analysis included both with laboratory diagnoses of influenza  as well as 
those with only clinical diagnoses bosed on symptoms.  A total of 629 
subjects were enrolled and randomized into one of three ueatment arms: 
standard dose oseltamivir, "high dose" oseltamivir, and placebo.  In both 
oseltamivirgroups the mean illness duration was reduced from 103 to 70 
hours.  The symptom severity decreased in the mated group by  40%. 
Additional studies analyzed the effect of neuraminidase inhibitors both 
in acute disease as well as in prevention.'  In one of these studies, 837 
relatives of sick family members who developed influenza were treated 
prophylactically with either placebo or zanamivic  We  20% of  the 
placebo group became ill, only 4% of the drug-treated group became ill.  In 
addition, this study also provided treament lo the index case family 
member and this resulted in a 2,.5  day reduction in illness over placebo. 
DNA viral sequences were performed in this study and no mislant flu 
strains developed. 
A novel study analyzed the effects of oscllamivir in  human volunteers 
in an experimentally induced influenza9 In aconmlled "laboratory" 
environment, these volunteers were directly inoculated inmasally with 
influenza  A:  Texas 36/91 HhT One group had osellamivir begun 26 
hours before virus inoculation and another group 28 hours after inocula- 
tion.  In the propbylactic group, 38% of patients developed influenza 
compared with 67% of placebo. In the past-treatment group, the dmion 
of illness was reduced hm  95 hours to 53 hours and the severiy was 
reduced by  50% compared to placebo. 